Hiprex
(methenamine hippurate)ApprovedSmall molecule
Hiprex is one of 2 small molecule programs targeting Overactive Bladder (OAB). It is currently in Approved.
1
Indications
6
Total Trials
1
Active Trials
1
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Overactive Bladder (OAB)
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prevention2 trials
Recurrent Uti1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
HIPREX
NDA NDA017681
Jan 1, 1982
UREX
NDA NDA016151
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for methenamine hippurate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]